Intralesional treatment with interleukin-2 (Proleukin) [aldesleukin] in soft tissue melanoma metastases. A phase II, prospective, open, multicenter trial.

Trial Profile

Intralesional treatment with interleukin-2 (Proleukin) [aldesleukin] in soft tissue melanoma metastases. A phase II, prospective, open, multicenter trial.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Aug 2011

At a glance

  • Drugs Aldesleukin (Primary)
  • Indications Cancer metastases; Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Aug 2011 Lead trial investigator (Claus Garbe) identified as reported by ClinicalTrials.gov.
    • 18 Aug 2011 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
    • 18 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top